Renal Intervention to Treat Hypertension

go back to reference Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.PubMed Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.PubMed

go back to reference Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10–7.PubMedCrossRef Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10–7.PubMedCrossRef

go back to reference Gruntzig A, Kuhlmann U, Vetter W, Lutolf U, Meier B, Siegenthaler W. Treatment of renovascular hypertension with percutaneous transluminal dilatation of a renal-artery stenosis. Lancet. 1978;1:801–2.PubMedCrossRef Gruntzig A, Kuhlmann U, Vetter W, Lutolf U, Meier B, Siegenthaler W. Treatment of renovascular hypertension with percutaneous transluminal dilatation of a renal-artery stenosis. Lancet. 1978;1:801–2.PubMedCrossRef

go back to reference Klow NE, Paulsen D, Vatne K, Rokstad B, Lien B, Fauchald P. Percutaneous transluminal renal artery angioplasty using the coaxial technique. Ten years of experience from 591 procedures in 419 patients. Acta Radiol. 1998;39:594–603.PubMedCrossRef Klow NE, Paulsen D, Vatne K, Rokstad B, Lien B, Fauchald P. Percutaneous transluminal renal artery angioplasty using the coaxial technique. Ten years of experience from 591 procedures in 419 patients. Acta Radiol. 1998;39:594–603.PubMedCrossRef

go back to reference Cragg AH, Smith TP, Thompson BH, et al. Incidental fibromuscular dysplasia in potential renal donors: long-term clinical follow-up. Radiology. 1989;172:145–7.PubMed Cragg AH, Smith TP, Thompson BH, et al. Incidental fibromuscular dysplasia in potential renal donors: long-term clinical follow-up. Radiology. 1989;172:145–7.PubMed

go back to reference Neymark E, LaBerge JM, Hirose R, et al. Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery. Radiology. 2000;214:755–60.PubMed Neymark E, LaBerge JM, Hirose R, et al. Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery. Radiology. 2000;214:755–60.PubMed

go back to reference Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–654.PubMedCrossRef Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–654.PubMedCrossRef

go back to reference Subramanian R, White CJ, Rosenfield K, et al. Renal fractional flow reserve: a hemodynamic evaluation of moderate renal artery stenoses. Catheter Cardiovasc Interv. 2005;64:480–6.PubMedCrossRef Subramanian R, White CJ, Rosenfield K, et al. Renal fractional flow reserve: a hemodynamic evaluation of moderate renal artery stenoses. Catheter Cardiovasc Interv. 2005;64:480–6.PubMedCrossRef

go back to reference Mitchell JA, Subramanian R, White CJ, et al. Predicting blood pressure improvement in hypertensive patients after renal artery stent placement: renal fractional flow reserve. Catheter Cardiovasc Interv. 2007;69:685–9.PubMedCrossRef Mitchell JA, Subramanian R, White CJ, et al. Predicting blood pressure improvement in hypertensive patients after renal artery stent placement: renal fractional flow reserve. Catheter Cardiovasc Interv. 2007;69:685–9.PubMedCrossRef

go back to reference Albertal M, Nau G, Padilla LT, Cura FA, Thierer J, Belardi JA. Do men and women respond differently to percutaneous renal artery interventions? Angiology 61:216–21. Albertal M, Nau G, Padilla LT, Cura FA, Thierer J, Belardi JA. Do men and women respond differently to percutaneous renal artery interventions? Angiology 61:216–21.

go back to reference Trani C, Tommasino A, Giammarinaro M, et al. Renal artery stenting in patients with chronic ischemic heart disease. Catheter Cardiovasc Interv 76:26–34. Trani C, Tommasino A, Giammarinaro M, et al. Renal artery stenting in patients with chronic ischemic heart disease. Catheter Cardiovasc Interv 76:26–34.

go back to reference • Marcantoni C, Zanoli L, Rastelli S, et al. Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial. J Nephrol 2009;22:13–6. This ongoing study is designed to assess the efficacy of PTRS for RAS in the population of patients with coronary artery disease. PubMed • Marcantoni C, Zanoli L, Rastelli S, et al. Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial. J Nephrol 2009;22:13–6. This ongoing study is designed to assess the efficacy of PTRS for RAS in the population of patients with coronary artery disease. PubMed

go back to reference Singer GM, Remetz MS, Curtis JP, Setaro JF. Impact of baseline renal function on outcomes of renal artery stenting in hypertensive patients. J Clin Hypertens (Greenwich). 2009;11:615–20.CrossRef Singer GM, Remetz MS, Curtis JP, Setaro JF. Impact of baseline renal function on outcomes of renal artery stenting in hypertensive patients. J Clin Hypertens (Greenwich). 2009;11:615–20.CrossRef

go back to reference Mulumudi MS, White CJ. Renal frame count: a quantitative angiographic assessment of renal perfusion. Catheter Cardiovasc Interv. 2005;65:183–6.PubMedCrossRef Mulumudi MS, White CJ. Renal frame count: a quantitative angiographic assessment of renal perfusion. Catheter Cardiovasc Interv. 2005;65:183–6.PubMedCrossRef

go back to reference Mahmud E, Smith TW, Palakodeti V, et al. Renal frame count and renal blush grade: quantitative measures that predict the success of renal stenting in hypertensive patients with renal artery stenosis. JACC Cardiovasc Interv. 2008;1:286–92.PubMedCrossRef Mahmud E, Smith TW, Palakodeti V, et al. Renal frame count and renal blush grade: quantitative measures that predict the success of renal stenting in hypertensive patients with renal artery stenosis. JACC Cardiovasc Interv. 2008;1:286–92.PubMedCrossRef

go back to reference Marini M, Fernandez-Rivera C, Cao I, et al. Treatment of transplant renal artery stenosis by percutaneous transluminal angioplasty and/or stenting: study in 63 patients in a single institution. Transplant Proc;43:2205–7. Marini M, Fernandez-Rivera C, Cao I, et al. Treatment of transplant renal artery stenosis by percutaneous transluminal angioplasty and/or stenting: study in 63 patients in a single institution. Transplant Proc;43:2205–7.

go back to reference Abate MT, Kaur J, Suh H, Darras F, Mani A, Nord EP. The use of drug-eluting stents in the management of transplant renal artery stenosis. Am J Transplant;11:2235–41. Abate MT, Kaur J, Suh H, Darras F, Mani A, Nord EP. The use of drug-eluting stents in the management of transplant renal artery stenosis. Am J Transplant;11:2235–41.

go back to reference Zierler RE, Bergelin RO, Davidson RC, Cantwell-Gab K, Polissar NL, Strandness Jr DE. A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. Am J Hypertens. 1996;9:1055–61.PubMedCrossRef Zierler RE, Bergelin RO, Davidson RC, Cantwell-Gab K, Polissar NL, Strandness Jr DE. A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. Am J Hypertens. 1996;9:1055–61.PubMedCrossRef

go back to reference Schreiber MJ, Pohl MA, Novick AC. The natural history of atherosclerotic and fibrous renal artery disease. Urol Clin North Am. 1984;11:383–92.PubMed Schreiber MJ, Pohl MA, Novick AC. The natural history of atherosclerotic and fibrous renal artery disease. Urol Clin North Am. 1984;11:383–92.PubMed

go back to reference Mailloux LU, Bellucci AG, Napolitano B, Mossey T, Wilkes BM, Bluestone PA. Survival estimates for 683 patients starting dialysis from 1970 through 1989: identification of risk factors for survival. Clin Nephrol. 1994;42:127–35.PubMed Mailloux LU, Bellucci AG, Napolitano B, Mossey T, Wilkes BM, Bluestone PA. Survival estimates for 683 patients starting dialysis from 1970 through 1989: identification of risk factors for survival. Clin Nephrol. 1994;42:127–35.PubMed

go back to reference Zeller T, Frank U, Muller C, et al. Stent-supported angioplasty of severe atherosclerotic renal artery stenosis preserves renal function and improves blood pressure control: long-term results from a prospective registry of 456 lesions. J Endovasc Ther. 2004;11:95–106.PubMedCrossRef Zeller T, Frank U, Muller C, et al. Stent-supported angioplasty of severe atherosclerotic renal artery stenosis preserves renal function and improves blood pressure control: long-term results from a prospective registry of 456 lesions. J Endovasc Ther. 2004;11:95–106.PubMedCrossRef

go back to reference Dichtel LE, Gurevich D, Rifkin B, Varma P, Concato J, Peixoto AJ. Renal artery revascularization in patients with atherosclerotic renal artery stenosis and impaired renal function: conservative management versus renal artery stenting. Clin Nephrol;74:113–22. Dichtel LE, Gurevich D, Rifkin B, Varma P, Concato J, Peixoto AJ. Renal artery revascularization in patients with atherosclerotic renal artery stenosis and impaired renal function: conservative management versus renal artery stenting. Clin Nephrol;74:113–22.

go back to reference Chang JH, Kim BS, Oh HJ, et al. Effect of baseline glomerular filtration rate on renal function following stenting for atherosclerotic renal artery stenosis. Scand J Urol Nephrol;44:169–74. Chang JH, Kim BS, Oh HJ, et al. Effect of baseline glomerular filtration rate on renal function following stenting for atherosclerotic renal artery stenosis. Scand J Urol Nephrol;44:169–74.

go back to reference Kalra PA, Chrysochou C, Green D, et al. The benefit of renal artery stenting in patients with atheromatous renovascular disease and advanced chronic kidney disease. Catheter Cardiovasc Interv;75:1–10. Kalra PA, Chrysochou C, Green D, et al. The benefit of renal artery stenting in patients with atheromatous renovascular disease and advanced chronic kidney disease. Catheter Cardiovasc Interv;75:1–10.

go back to reference Crutchley TA, Pearce JD, Craven TE, Stafford JM, Edwards MS, Hansen KJ. Clinical utility of the resistive index in atherosclerotic renovascular disease. J Vasc Surg 2009;49:148–55, 155 e1–3; discussion 155. Crutchley TA, Pearce JD, Craven TE, Stafford JM, Edwards MS, Hansen KJ. Clinical utility of the resistive index in atherosclerotic renovascular disease. J Vasc Surg 2009;49:148–55, 155 e1–3; discussion 155.

go back to reference Davies MG, Saad WE, Bismuth JX, Naoum JJ, Peden EK, Lumsden AB. Endovascular revascularization of renal artery stenosis in the solitary functioning kidney. J Vasc Surg. 2009;49:953–60.PubMedCrossRef Davies MG, Saad WE, Bismuth JX, Naoum JJ, Peden EK, Lumsden AB. Endovascular revascularization of renal artery stenosis in the solitary functioning kidney. J Vasc Surg. 2009;49:953–60.PubMedCrossRef

go back to reference Urbschat A, Obermuller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers;16 Suppl 1:S22–30. Urbschat A, Obermuller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers;16 Suppl 1:S22–30.

go back to reference Hiramoto J, Hansen KJ, Pan XM, Edwards MS, Sawhney R, Rapp JH. Atheroemboli during renal artery angioplasty: an ex vivo study. J Vasc Surg. 2005;41:1026–30.PubMedCrossRef Hiramoto J, Hansen KJ, Pan XM, Edwards MS, Sawhney R, Rapp JH. Atheroemboli during renal artery angioplasty: an ex vivo study. J Vasc Surg. 2005;41:1026–30.PubMedCrossRef

go back to reference Al-Mubarak N, Roubin GS, Vitek JJ, Iyer SS, New G, Leon MB. Effect of the distal-balloon protection system on microembolization during carotid stenting. Circulation. 2001;104:1999–2002.PubMedCrossRef Al-Mubarak N, Roubin GS, Vitek JJ, Iyer SS, New G, Leon MB. Effect of the distal-balloon protection system on microembolization during carotid stenting. Circulation. 2001;104:1999–2002.PubMedCrossRef

go back to reference Kawarada O, Yokoi Y, Takemoto K. The characteristics of dissemination of embolic materials during renal artery stenting. Catheter Cardiovasc Interv. 2007;70:784–8.PubMedCrossRef Kawarada O, Yokoi Y, Takemoto K. The characteristics of dissemination of embolic materials during renal artery stenting. Catheter Cardiovasc Interv. 2007;70:784–8.PubMedCrossRef

go back to reference •• Cooper CJ, Haller ST, Colyer W, et al. Embolic protection and platelet inhibition during renal artery stenting. Circulation 2008;117:2752–60. This is the first randomized study to demonstrate preservation of renal function during PTRS if both an EPD and a GP IIb/IIIa agent are used during the procedure. The population studied was small. A larger trial is warranted to confirm these data.PubMedCrossRef •• Cooper CJ, Haller ST, Colyer W, et al. Embolic protection and platelet inhibition during renal artery stenting. Circulation 2008;117:2752–60. This is the first randomized study to demonstrate preservation of renal function during PTRS if both an EPD and a GP IIb/IIIa agent are used during the procedure. The population studied was small. A larger trial is warranted to confirm these data.PubMedCrossRef

go back to reference • Kanjwal K, Cooper CJ, Virmani R, et al. Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy. Catheter Cardiovasc Interv 2010;76:16–23. This post hoc analysis of the RESIST trial demonstrates the efficacy of GP IIb/IIIa inhibition in preserving renal function during PTRS via prevention of platelet-rich thromboli. A larger trial is warranted to confirm these data. PubMedCrossRef • Kanjwal K, Cooper CJ, Virmani R, et al. Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy. Catheter Cardiovasc Interv 2010;76:16–23. This post hoc analysis of the RESIST trial demonstrates the efficacy of GP IIb/IIIa inhibition in preserving renal function during PTRS via prevention of platelet-rich thromboli. A larger trial is warranted to confirm these data. PubMedCrossRef

go back to reference Thatipelli MR, Misra S, Sanikommu SR, Schainfeld RM, Sharma SK, Soukas PA. Embolic protection device use in renal artery stent placement. J Vasc Interv Radiol. 2009;20:580–6.PubMedCrossRef Thatipelli MR, Misra S, Sanikommu SR, Schainfeld RM, Sharma SK, Soukas PA. Embolic protection device use in renal artery stent placement. J Vasc Interv Radiol. 2009;20:580–6.PubMedCrossRef

go back to reference Laird JR, Tehrani F, Soukas P, Joye J, Ansel G, Rocha-Singh K. Feasibility of fibernet(R) embolic protection system in patients undergoing angioplasty for atherosclerotic renal artery stenosis. Catheter Cardiovasc Interv. Laird JR, Tehrani F, Soukas P, Joye J, Ansel G, Rocha-Singh K. Feasibility of fibernet(R) embolic protection system in patients undergoing angioplasty for atherosclerotic renal artery stenosis. Catheter Cardiovasc Interv.

go back to reference • Jaffe M.O. obotHi. Does Elevated Brain Natriuretic Peptide (BNP) Predict Outcomes for Patients with Uncontrolled Hypertension in Renal Artery Stenting? Society for Cardiovascular Angiography and Intervention 2011 Scientic Sessions. Baltimore, MD, 2011. These data supported FDA approval of the Herculink stent system for PTRS of atherosclerotic RAS. • Jaffe M.O. obotHi. Does Elevated Brain Natriuretic Peptide (BNP) Predict Outcomes for Patients with Uncontrolled Hypertension in Renal Artery Stenting? Society for Cardiovascular Angiography and Intervention 2011 Scientic Sessions. Baltimore, MD, 2011. These data supported FDA approval of the Herculink stent system for PTRS of atherosclerotic RAS.

go back to reference van de Ven PJ, Kaatee R, Beutler JJ, et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. Lancet. 1999;353:282–6.PubMedCrossRef van de Ven PJ, Kaatee R, Beutler JJ, et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. Lancet. 1999;353:282–6.PubMedCrossRef

go back to reference Blum U, Krumme B, Flugel P, et al. Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. N Engl J Med. 1997;336:459–65.PubMedCrossRef Blum U, Krumme B, Flugel P, et al. Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. N Engl J Med. 1997;336:459–65.PubMedCrossRef

go back to reference Henry M, Amor M, Henry I, et al. Stents in the treatment of renal artery stenosis: long-term follow-up. J Endovasc Surg. 1999;6:42–51.PubMedCrossRef Henry M, Amor M, Henry I, et al. Stents in the treatment of renal artery stenosis: long-term follow-up. J Endovasc Surg. 1999;6:42–51.PubMedCrossRef

go back to reference Rocha-Singh KJ, Mishkel GJ, Katholi RE, et al. Clinical predictors of improved long-term blood pressure control after successful stenting of hypertensive patients with obstructive renal artery atherosclerosis. Catheter Cardiovasc Interv. 1999;47:167–72.PubMedCrossRef Rocha-Singh KJ, Mishkel GJ, Katholi RE, et al. Clinical predictors of improved long-term blood pressure control after successful stenting of hypertensive patients with obstructive renal artery atherosclerosis. Catheter Cardiovasc Interv. 1999;47:167–72.PubMedCrossRef

go back to reference Tuttle KR, Chouinard RF, Webber JT, et al. Treatment of atherosclerotic ostial renal artery stenosis with the intravascular stent. Am J Kidney Dis. 1998;32:611–22.PubMedCrossRef Tuttle KR, Chouinard RF, Webber JT, et al. Treatment of atherosclerotic ostial renal artery stenosis with the intravascular stent. Am J Kidney Dis. 1998;32:611–22.PubMedCrossRef

go back to reference Zeller T, Muller C, Frank U, et al. Gold coating and restenosis after primary stenting of ostial renal artery stenosis. Catheter Cardiovasc Interv 2003;60:1–6; discussion 7–8. Zeller T, Muller C, Frank U, et al. Gold coating and restenosis after primary stenting of ostial renal artery stenosis. Catheter Cardiovasc Interv 2003;60:1–6; discussion 7–8.

go back to reference Davies MG, Saad WA, Bismuth JX, Peden EK, Naoum JJ, Lumsden AB. Outcomes of endoluminal reintervention for restenosis after percutaneous renal angioplasty and stenting. J Vasc Surg. 2009;49:946–52.PubMedCrossRef Davies MG, Saad WA, Bismuth JX, Peden EK, Naoum JJ, Lumsden AB. Outcomes of endoluminal reintervention for restenosis after percutaneous renal angioplasty and stenting. J Vasc Surg. 2009;49:946–52.PubMedCrossRef

go back to reference Stone PA, Campbell JE, Aburahma AF, et al. Ten-year experience with renal artery in-stent stenosis. J Vasc Surg;53:1026–31. Stone PA, Campbell JE, Aburahma AF, et al. Ten-year experience with renal artery in-stent stenosis. J Vasc Surg;53:1026–31.

go back to reference Zeller T, Rastan A, Kliem M, et al. Impact of carbon coating on the restenosis rate after stenting of atherosclerotic renal artery stenosis. J Endovasc Ther. 2005;12:605–11.PubMedCrossRef Zeller T, Rastan A, Kliem M, et al. Impact of carbon coating on the restenosis rate after stenting of atherosclerotic renal artery stenosis. J Endovasc Ther. 2005;12:605–11.PubMedCrossRef

go back to reference Nolan BW, Schermerhorn ML, Powell RJ, et al. Restenosis in gold-coated renal artery stents. J Vasc Surg. 2005;42:40–6.PubMedCrossRef Nolan BW, Schermerhorn ML, Powell RJ, et al. Restenosis in gold-coated renal artery stents. J Vasc Surg. 2005;42:40–6.PubMedCrossRef

go back to reference Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003;107:559–64.PubMedCrossRef Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003;107:559–64.PubMedCrossRef

go back to reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (GREAT Trial): angiographic follow-up after 6 months and clinical outcome up to 2 years. J Endovasc Ther. 2007;14:460–8.PubMedCrossRef Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (GREAT Trial): angiographic follow-up after 6 months and clinical outcome up to 2 years. J Endovasc Ther. 2007;14:460–8.PubMedCrossRef

go back to reference Kiernan TJ, Yan BP, Eisenberg JD, et al. Treatment of renal artery in-stent restenosis with sirolimus-eluting stents. Vasc Med;15:3–7. Kiernan TJ, Yan BP, Eisenberg JD, et al. Treatment of renal artery in-stent restenosis with sirolimus-eluting stents. Vasc Med;15:3–7.

go back to reference Hoobler SW, Manning JT, Paine WG, et al. The effects of splanchnicectomy on the blood pressure in hypertension; a controlled study. Circulation. 1951;4:173–83.PubMed Hoobler SW, Manning JT, Paine WG, et al. The effects of splanchnicectomy on the blood pressure in hypertension; a controlled study. Circulation. 1951;4:173–83.PubMed

go back to reference Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953;1:403–8.PubMedCrossRef Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953;1:403–8.PubMedCrossRef

go back to reference DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75–197.PubMed DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75–197.PubMed

go back to reference Converse Jr RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–8.PubMedCrossRef Converse Jr RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–8.PubMedCrossRef

go back to reference Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.PubMedCrossRef Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.PubMedCrossRef

go back to reference • Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911–7. This is the longest durability study of catheter-based renal sympathetic denervation for controlling hypertension. Eighteen patients were followed for 24 months. A larger study is warranted to confirm these data. • Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911–7. This is the longest durability study of catheter-based renal sympathetic denervation for controlling hypertension. Eighteen patients were followed for 24 months. A larger study is warranted to confirm these data.

go back to reference •• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903–9. This is the largest catheter-based renal sympathetic denervation trial published to date. These data demonstrate the safety and efficacy of this technique. PubMedCrossRef •• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903–9. This is the largest catheter-based renal sympathetic denervation trial published to date. These data demonstrate the safety and efficacy of this technique. PubMedCrossRef

go back to reference Voskuil M, Verloop WL, Blankestijn PJ, Agostoni P, Stella PR, Doevendans PA. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J;19:319–23. Voskuil M, Verloop WL, Blankestijn PJ, Agostoni P, Stella PR, Doevendans PA. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J;19:319–23.

go back to reference Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension;58:559–65. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension;58:559–65.

go back to reference Hansen JM, Abildgaard U, Fogh-Andersen N, et al. The transplanted human kidney does not achieve functional reinnervation. Clin Sci (Lond). 1994;87:13–20. Hansen JM, Abildgaard U, Fogh-Andersen N, et al. The transplanted human kidney does not achieve functional reinnervation. Clin Sci (Lond). 1994;87:13–20.